WeTrials
Recruiting

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

What is this study?

This study is testing a new medication called KIN-2787, both by itself and combined with another drug, to see how well it fights certain advanced solid tumors. Researchers want to find the safest and most effective dose to help people with specific gene changes in their cancer.

Who can participate?

Adults with advanced or metastatic solid tumors, such as lung cancer or skin cancer, that have specific BRAF or NRAS gene changes may join. Participants must also be able to do normal daily activities and be free of recent infections or certain stomach issues.

What will happen?

Participants will take the investigational study medication as pills and have regular check-ups to monitor their health, track how the drug affects the cancer, and review any side effects. The care team will closely watch your progress and guide you through each step.

Where and when?

The study is currently recruiting participants at locations in Los Angeles and San Diego, California. Your study doctor can give you more details about the exact clinic locations.

Key Points
  • 1Tests a new medication called KIN-2787 for advanced solid tumors.
  • 2Looking for adults with specific BRAF or NRAS genetic mutations.
  • 3Currently recruiting patients at multiple locations in California.

Related video

VJOncology: Dr Janice Mehnert on exarafenib phase 1 results in NRAS-mutant melanoma (November 2024)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Solid Tumor, AdultNon-small Cell Lung CancerMelanoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.